title: [Predictive factors for development of hemolytic uremic syndrome (HUS) and early intensive treatments for prevention of HUS enterohemorrhagic Escherichia coli infection].
abstract: Predictive factors for the development of hemolytic uremic syndrome (HUS) were evaluated in 88 inpatients who suffered from enterohemorrhagic E. coli infections in the outbreak in Sakai, 1996. All in- and outpatients received oral or intravenous fosfomycin within acute phase of hemorrhagic colitis, and HUS complicated 1.4% of them. Persistence of bloody stools and diarrhea were longer in HUS patients than in non-HUS patients, but persistence of abdominal pain was not different in either group. Leukocytosis with leukocyte counts over 15,000/microliters and/or elevated CRP level over 2.0 mg/dl at admission, and fever and/or vomiting in the course of hemorrhagic colitis were more frequent in HUS patients than in non-HUS patients. Early intensive treatments including gammaglobulin, urinastatin, aspirin, and dipyridamole were employed in 34 high risk patients for prevention of HUS. These patients were estimated to be at risk of developing HUS because of incomplete HUS, nephropathy, elevated LDH level, thrombocytopenia, or age younger than two years old. These treatments were clinically effective.
authors.affiliation: Department of Pediatrics, Bell Land Hospital.
authors.forename: T
authors.initials: T
authors.lastname: Oshima
mesh_terms: D015746:Abdominal Pain / Q000150:complications; D000293:Adolescent; D000367:Age Factors; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002648:Child; D003967:Diarrhea / Q000150:complications; D004176:Dipyridamole / Q000627:therapeutic use; D004927:Escherichia coli Infections / Q000150:complications*; D005260:Female; D005334:Fever; D005578:Fosfomycin / Q000627:therapeutic use; D006023:Glycoproteins / Q000627:therapeutic use; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007674:Kidney Diseases / Q000150:complications; D007958:Leukocyte Count; D008107:Liver Diseases / Q000150:complications; D008297:Male; D008551:Melena / Q000150:complications; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D012737:Sex Factors; D013997:Time Factors; D005719:gamma-Globulins / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D006023:Glycoproteins; D010975:Platelet Aggregation Inhibitors; D005719:gamma-Globulins; D005578:Fosfomycin; D004176:Dipyridamole; C028665:urinastatin; D001241:Aspirin